DRIVING POLICIES THAT MAKE A DIFFERENCE
NORD is the only U.S. organization working at the intersection of care, research and policy for all rare diseases and the more than 30 million Americans living with a rare disease. We are rooted in the advocacy that spurred a movement resulting in the passage of the world’s first law incentivizing drug development for rare diseases—the Orphan Drug Act of 1983. We continue to fight until every person living with a rare disease has access to affordable and life-changing care and treatment.

In 2024, we are working with federal and state decision-makers to advance the following key priorities:

New and Better Therapies
NORD advocates for the development of safe and effective therapies and better diagnostics, supporting policies that strengthen rare disease research, improving regulatory approval processes and protecting incentives for the development of rare disease treatments. In 2024, issues that advance this priority include:

• Maintain vital incentives for pediatric rare disease research by reauthorizing the Rare Pediatric Disease Priority Review Voucher program (H.R. 7384, the Creating Hope Reauthorization Act).
• Protect the integrity and intent of the Orphan Drug Act (ODA) in awarding orphan drug exclusivity by passing the RARE Act (S. 1214/H.R. 7383).
• Support programs that ensure strong regulatory pathways at the FDA and enable robust patient access to safe and effective therapies, such as strengthening pre-approval access by expanding Project Facilitate.
• Reduce barriers to clinical trial participation through methods such as greater decentralization and use of digital health technologies and give patients a voice through patient listening sessions, patient-focused drug development meetings, and at every step of drug development.

Access to Affordable Health Care and Treatment
NORD believes that all rare disease patients should have access to affordable, high-quality, comprehensive health care that best meets their complex medical needs. In 2024, issues that advance this priority include:

• Ensure drug pricing efforts related to the Inflation Reduction Act (IRA) and state-level Prescription Drug Affordability Boards (PDABs), and pharmacy benefits managers (PBM) reform truly benefit rare disease patients through reduced out-of-pocket prescription drug costs, while appropriately protecting continued innovation.
• Improve patient access to out-of-state health care providers by passing the Accelerating Kids Access to Care Act (S. 2372/H.R. 4758) and pushing additional states to join the Interstate Medical Licensure Compact.
• Increase the number of states with high functioning Rare Disease Advisory Councils (RDACs) to give the rare disease community a voice in state government.

Reducing the Diagnostic Odyssey
It can take years to get an accurate rare disease diagnosis, which can take a significant toll on an individual’s physical and mental health and contribute to significant financial burdens. In 2024, issues that advance this priority include:

• Expand availability and coverage of necessary genetic testing.
• Support robust, well-funded newborn screening programs in every state.
• Protect patient access to accurate diagnostic tools, including lab developed tests.

There are more than 10,000 known rare diseases. However, less than 5% have FDA-approved treatments.

Rare disease patients’ direct medical costs are 3-5 times higher than non-rare disease patients.

880+ orphan drugs have been FDA-approved since the passage of the Orphan Drug Act.

Looking for more information on NORD’s policy work? Visit: rarediseases.org/driving-policy Email: policy@rarediseases.org